Kovitz Investment Group Partners
SABS icon

Kovitz Investment Group Partners’s SAB Biotherapeutics SABS Stock Holding History

Kovitz Investment Group Partners’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,201
Closed -$38.6K – 1149
2025
Q3 		$38.6K Hold
19,201
– – ﹤0.01% 1386
2025
Q2 		$33.7K Hold
19,201
– – ﹤0.01% 1350
2025
Q1 		$26.1K Hold
19,201
– – ﹤0.01% 1238
2024
Q4 		$72.9K Hold
19,201
– – ﹤0.01% 1211
2024
Q3 		$51.8K Buy
+19,201
New +$53.2K ﹤0.01% 1005

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

Kovitz Investment Group Partners's SABS Position: Q4 2025 in Review

Kovitz Investment Group Partners sold out of SAB Biotherapeutics (SABS) in Q4 2025, closing a stake of 19,201 shares — an estimated $38.6K sold.

Kovitz Investment Group Partners first reported a position in SABS in Q3 2024 and held it in 5 quarters. The position peaked at $72.9K in Q4 2024. 48 funds tracked by Wall St. Rank hold SABS as of Q4 2025.

  • Kovitz Investment Group Partners reported no remaining SAB Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Kovitz Investment Group Partners sold 19,201 SAB Biotherapeutics shares in Q4 2025, an estimated $38.6K.
  • Kovitz Investment Group Partners first reported a position in SAB Biotherapeutics in Q3 2024 and held it in 5 quarters.
  • Kovitz Investment Group Partners's SAB Biotherapeutics position peaked at $72.9K in Q4 2024.
  • 48 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q4 2025.

Based on Kovitz Investment Group Partners's 13F filing for Q4 2025, filed 20 Feb 2026.